It didn’t sound like a dealbreaker, so she decided to try it.Two weeks after her third dose, Aaron was dead.She died last ...
With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...
Eisai Co, Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other ...
STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.
STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback